Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors-Reference-Cited by-同舟云学术

Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors

Published:2019-09-09 Issue:12 Volume:21 Page:2684-2693
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Yakovleva Tatiana¹^ORCID,Sokolov Victor¹^ORCID,Chu Lulu²,Tang Weifeng³^ORCID,Greasley Peter J.⁴,Peilot Sjögren Helena⁵,Johansson Susanne⁶,Peskov Kirill¹⁷^ORCID,Helmlinger Gabriel²^ORCID,Boulton David W.³^ORCID,Penland Robert C.²^ORCID

Affiliation:

1. M&S Decisions Moscow Russian Federation

2. Clinical Pharmacology & Safety Sciences, R&D BioPharmaceuticals, AstraZeneca Waltham Massachusetts

3. Clinical Pharmacology & Safety Sciences, R&D BioPharmaceuticals, AstraZeneca Gaithersburg Maryland

4. CVRM, R&D BioPharmaceuticals, AstraZeneca Gothenburg Sweden

5. Discovery Biology, Discovery Sciences, R&D BioPharmaceuticals, AstraZeneca Gothenburg Sweden

6. Clinical Pharmacology & Safety Sciences, R&D BioPharmaceuticals, AstraZeneca Gothenburg Sweden

7. I.M. Sechenov First Moscow State Medical University Moscow Russian Federation

Funder

AstraZeneca

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.13858

Reference32 articles.

1. World Health Organization (WHO). Diabetes Fact sheet #312. August2011.https://web.archive.org/web/20130826174444/http://www.who.int/mediacentre/factsheets/fs312/en/. Accessed July 31 2019.

2. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight

3. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia

4. Why Do SGLT2 Inhibitors Inhibit Only 30–50% of Renal Glucose Reabsorption in Humans?

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neomangiferin, a Naturally Occurring Mangiferin Congener, Inhibits Sodium-Glucose Co-transporter-2: An In silico Approach;Bioinformatics and Biology Insights;2024-01

2. Multifunctional nanoparticle-mediated combining therapy for human diseases;Signal Transduction and Targeted Therapy;2024-01-01

3. Dapagliflozin improves diabetic cognitive impairment via indirectly modulating the mitochondria homeostasis of hippocampus in diabetic mice;BioFactors;2023-08-19

4. Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches;Frontiers in Pharmacology;2023-06-01

5. SGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive Strategies;Frontiers in Bioscience-Landmark;2023-05-22